Sarah Howell, Ph.D., Chief Executive Officer
Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director. During her time at Arecor she has led the transformation of the business into a successful clinical stage biotechnology company. Sarah has a background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas.
Susan Lowther, Chief Financial Officer and Company Secretary
Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies. Susan joined Arecor from IXICO plc, an imaging contract research organisation where she defined the financing strategy and raised growth capital taking the company on a path to profitability.
Jan Jezek, Ph.D., Chief Scientific Officer
Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.
Lindsey Foulkes, Ph.D. Chief Operating Officer
Lindsey was appointed Chief Operations Officer of Arecor in 2021 and is responsible for the management of operations and business development. Lindsey has a background in senior positions at life sciences companies, having previously been Senior Director, Business Development- Small Molecules at Liminal Biosciences, and Head of Strategic Business Development at Cangene Corporation.
David Gerring, VP, Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
Fiona Lawrence, VP, Clinical & Regulatory Affairs and QA
Fiona Lawrence is a pharmaceutical research and development professional and, as VP, Clinical & Regulatory Affairs and QA at Arecor, she has responsibility for driving the clinical development of Arecor’s proprietary portfolio.
Jim MacDonald-Clink, VP, Business Development
Jim MacDonald-Clink joined Arecor in November 2019 as VP, Business Development. Jim has over 25 years’ experience in healthcare, having previously worked at Mundipharma, where he was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. He also held roles at Astellas Pharma and Fujisawa. His experience includes various roles in R&D, Medical and Commercial functions.